Enumeration of megakaryocytes number in thrombocytopenic patients by immunohistochemistry

Doaa I. Elzaeem, Esmat A El Sharkawe, Ayman G Ghobrial, Waleed M Abd El-Hamed, Aliaa S Abd El Fatah


Background and objectives: The aim of the present study is to enumerate megakaryocytes in vivo in patients with thrombocytopenia.

 Subjects and methods: The study was carried out on 20 ITP (group I) patients and 20 thrombocytopenic patients with myelodysplastic syndrome (groupII) who were admitted to minia university hospital . Serial histological sections from bone marrow biopsies were stained for CD61. The number of bone marrow megakaryocytes were determined morphologically .Results: Megakaryocytes number was increased in ITP and MDS patients (group I & II ) and there was no statistically  significant difference  between both groups  (Mean ± SD 8.1 ±5.1 vs. 6 ±3.1 cells per HPF; p=0.271). Conclusion: researches in ITP should focus on ultrastructure of megakaryocytes and its relation to antibody.


ITP, megakaryocytes, antibody specificity


Deutschman, C. S., & Neligan, P. J. (2010).Evidence-based Practice of Critical Care. Elsevier Health Sciences. ISBN 1416054766. Retrieved 2015-04-30.

Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol. 2014;20:714-23.

Despotovic, J .M.,Blom, N. R.,Esselink, M .T.,Koornstra ,J .J.,Smit, J. W.,Louwes, H.,Vellenga, E.,de Wolf, J .T.(2018).Immune Hematology:Diagnosis and management of autoimmune cytopenia.part I :3-45.https://books.google.com.eg/books?isbn=3391732692.

Arnold ,D.M., Nazi, I., Toltl, L.J., Ross, C., Ivetic ,N., Smith, J.W., Liu, Y., Kelton ,J.G. (2015)Antibody binding to megakaryocytes in vivo in patients with immune thrombocytopenia. Eur J Haematol. doi:10.1111/ejh.12528

Tripathi, A.K., Mishra, S., Kumar ,A., Yadav, D., Shukla ,A., Yadav, Y.(2014) Megakaryocyte morphology and its impact in predicting response to steroid in immune thrombocytopenia. Platelets.;25:526-31.

Limarzi M, Schleicher EM. The Reaction of Peripheral Blood and Bone Marrow in Chronic Hemorrhage and Essential Thrombopenic Purpura. JAMA 1940;114:12–8.

Cheng, G., Saleh, M. N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., Arning, M., Stone, N. L., and Bussel, J. B.(2011). Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet ; 377: 393-402.

Harker LA. Thrombokinetics in idiopathic thrombocytopenic purpura. Br J Haematol1970;19:95–104.

Lev, P. R., Grodzielski, M., Goette, N. P., Glembotsky, A. C., Espasandin, Y. R.,Pierdominici, M. S., Contrufo, G., Montero, V. S., Ferrari, L., Molinas, F. C., Heller, P. G., and Marta, R. F.(2014). Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count. Br J Haematol .

Mahabir, V. K., Ross, C., Popovic, S., Sur, M. L., Bourgeois, J., Lim, W., George, J. N.,Wang, G., Cook, R. J., Toltl, L. J., Nazi, I., Kelton, J. G., and Arnold, D. M.(2013). A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia. Eur J Haematol ; 90: 121-126.

Vinci G, Tabilio A, Deschamps JF, van Haeke D, Henri A et al.(1984): Immunological study of in vitro maturation of human megakaryocytes. Br J Haematol ;56:589-605.

Iraqi M, Perdomo J, Yan F, Choi PY-I, and Chong B.(2015).Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.Haematologica. ; 100(5): 623–32.


  • There are currently no refbacks.